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Abstract
Background: Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired
resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. Here, we
report the successful treatment with alternating chemotherapy and TKIs of two cases of advanced NSCLC who
developed resistance to TKI.
Case presentation: Two patients with advanced or metastatic NSCLC were treated with palliative chemotherapy
followed by erlotinib/gefitinib. When TKI therapy failed, two cycles of chemotherapy were provided, which were
followed by re-challenge with erlotinib or gefitinib.
Conclusion: NSCLC patients with acquired TKI resistance should be managed aggressively whenever possible.
Subsequent chemotherapy and target treatment is one of the reasonable choices for those with an initial dramatic
clinical response with erlotinib/gefitinib treatment. Further studies are warranted to substantiate the association of
erlotinib /gefitinib treatment with the efficacy of NSCLC patients with acquired TKI failure.
Background
Lung cancer is a leading cause of cancer-related death
throughout the world and its death toll reached 7.4 million
or approximately 13% of all deaths worldwide in 2004.
Early diagnosis of lung cancer is difficult due to the
insidious nature of symptoms and most patients have
progressed to an advanced stage at the time of diagnosis.
Multiple studies have clearly shown that chemotherapy is
important in the palliative care of advanced non-small cell
lung cancer (NSCLC) even compared with the best sup-
portive treatment. Chemotherapy as the main treatment
approach for advanced lung cancer can improve patient
survival and their quality of life [1].
Erlotinib and gefitinib, as oral epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs), are
commonly used as second- or third-line drugs [2,3], and
are sometimes also used in first-line therapy for advanced
or metastatic NSCLC [4,5]. Despite an initial dramatic
response, most patients treated with these two agents
will eventually develop progressive disease. Few reports
have reported on treatment options after acquired TKI
failure. In the current report, we present two cases of
advanced NSCLC. One patient received and benefited
from gefitinib, and the other from erlotinib after repeated
cycles of palliative chemotherapy and targeted therapy.
The two patients are still in good conditions and alive
3-4 years after diagnosis with advanced lung cancer.
Case presentation
Case one
In June 2007, a 70-year-old non-smoking female was
seen at our hospital because of a 3-month history of
progressive dysponea at rest. CT scan revealed a mass at
the right lower lobe and moderate pleural effusion on
the right side. Metastasis to right adrenal gland was
observed on abdominal CT. There was no evidence of
e x t r at h o r a c i cm e t a s t a s i so nb r a i nM R Ia n db o n eE C T
scans. Lung needle aspiration revealed adenocarcinoma
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She started 4 cycles of systemic chemotherapy with cis-
platin and gemcitabine in Jul 2007. CT scan showed a
stable disease of the carcinoma and marked clinical
improvement was noted as dyspnoea disappeared and
the patient reported a general feeling of wellness. The
patient then received two cycles of docetaxel for mainte-
nance therapy. In the following six months, the patient
was well without any evidence of local or systemic
recurrence. In June 2008 a routine follow-up bone ECT
and brain MRI revealed bone and brain metastatic
lesions, and the patient commenced erlotinib (150 mg
daily ), which she tolerated well and only experienced
grade 1 skin rash without requiring dose adjustment.
After 4 weeks of erlotinib, the patient showed complete
response in her intracranial disease and a partial
response in her lung disease. After 12 months of erloti-
nib therapy, tumor at the right lower lobe progressed,
and two cycles of carboplatin and paclitaxel were admi-
nistered. CT imaging confirmed stable disease in the
right lower lobe tumor. However, the patient refused
further cytotoxic chemotherapy because of severe treat-
ment-related diarrhea. She was re-challenged with erloti-
nib (150 mg daily ) in October 2009, and experienced
grade 3 skin rash without dose modification. Fortu-
nately, she improved clinically with her right lower lobe
tumor showing partial response after 4 weeks of erloti-
nib treatment and the treatment was continued for ele-
ven more months(CT scans were shown in Figure 1).
Case two
In September 2006, a 50-year-old non-smoking female
was seen by us because of a 4-month history of non-
productive cough and shortness of breath. A mass in
the left upper lobe and multiple lesions in both lungs
were observed on chest CT, and multiple bone involve-
ments were found on ECT. Lung fine-needle aspiration
showed the presence of adenocarcinoma. She was initi-
ally treated with 4 cycles of systemic chemotherapy with
cisplatin and gemcitabine. CT scans demonstrated pro-
gressive disease. She was administered two cycles of
docetaxel, and a progressive disease was noted in the
lung disease. Therefore, she commenced gefitinib (250
mg daily) as third-line therapy in May 2007. She toler-
ated the regimen well and only experienced grade 1
diarrhea. After 4 weeks of gefitinib, the patient showed
partial response in her lung disease. After 29 months of
gefitinib, the patient developed brain metastases and the
tumor also spread to the right lung. Brain radiotherapy
(25 Gy/five fractions) was administered followed by two
cycles of carboplatin and paclitaxel. Chemotherapy,
however, was terminated because of severe hematologi-
cal toxicity. She was re-challenged with gefitinib (250
mg daily) in Nov 2009 and experienced grade 1 skin
rash and diarrhea. After 4 weeks of gefitinib, a CT scan
showed a marked regression in the right lung tumor
and intracranial disease, Stable disease was noted in the
left lung tumor. So far, the patient continued gefitinib
treatment(CT scans were shown in Figure 2).
Discussion
Systemic chemotherapy has played an important role in
the palliative care of advanced NSCLC. Both quantita-
tive and qualitative benefits have been noted with plati-
num-based 2-drug chemotherapeutic regimens in
advanced NSCLC patients with a good performance
status [6,7].
Patients with advanced NSCLC, however, eventually
r e l a p s eo rb e c o m er e f r a c t o r yt of i r s t - l i n et r e a t m e n t .
Acceptable toxicity and improved quality of life are
especially important for those patients in second-line
therapy. Docetaxel and pemetrexed, have demonstrated
efficacy and been approved as second-line therapy for
patients with advanced or metastatic NSCLC [8-10].
Meanwhile, for patients who do not respond to first-line
chemotherapy or who tolerate it poorly, an EGFR inhibi-
tor may be the preferred choice in second line therapy.
Erlotinib and gefitinib are EGFR TKIs that suppress
intracellular signaling pathways, which normally pro-
mote cell growth and proliferation [11]. They have no
cumulative hematologic toxicities, allowing for a longer
duration of treatment. In the current study, erlotinib
was administered as the second-line drug in one case
and gefitinib as the third-line drug in the other case,
and a long-term disease control was obtained from
EGFR TKI treatment. Most patients treated with these
agents, however, had progressive disease even after
showing an initial dramatic response. Then, the strategy
of treatment in the next step is of importance.
Currently, there is no clear evidence suggesting an
optimal treatment strategy for patients with acquired
TKI failure. Some trials are investigating the role of
anticancer therapies in the third- or fourth-line setting
after EGFR TKI failure. An irreversible TKI targeting
the EGFR, HER2, and vascular endothelial growth factor
receptor was evaluated in the third- and fourth-line set-
tings after EGFR TKI failure [12]. A small molecule Met
inhibitor combined with an EGFR TKI has proven to be
a reasonable strategy to overcome erlotinib-resistant
T790M NSCLC [13]. Combining an insulin-like growth
factor inhibitor with erlotinib to reverse resistance to
erlotinib is also under investigation [14]. However, most
of these treatments are not clinically available. Subse-
quent chemotherapy was investigated after acquired TKI
resistance and improved survival outcome in advanced
NSCLC [15].
Our current two cases highlighted good responses to
erlotinib/ gefitinib, and had obtained long-term stable
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Page 2 of 5Figure 1 Case 1. Serial contrast-enhanced CT scans of the chest. (a) one month after erlotinib therapy; (b) CT showing an increase in size of
the lung nodule after 12 months of erlotinib therapy; (c) CT showing a stable disease of the lung nodule after two cycles of chemotherapy;
(d) CT showing a shrinkage of the tumor in the right lower lobe after 4 weeks of erlotinib re-challenge.
Figure 2 Case 2. Serial contrast-enhanced CT scans of the chest. (a) one month after gefitinib therapy; (b) CT scan showing a new lesion at
the right lund after 29 months of gefitinib therapy; (c) CT showing a stable disease of the lung nodule after two cycles of chemotherapy; (d) CT
scan showing a marked regression of the tumor in the right lung, and stable disease of the tumor in the left lung after one month of gefitinib
re-challenge.
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When the patients developed acquired resistance to
EGFR TKIs, two cycles of a taxane-based chemotherapy
was selected, after which erlotinib/gefitinib was adminis-
tered again, which yielded more than ten months pro-
gression-free survival. Restored sensitivity to EGFR-TKIs
after chemotherapy may be due to the following mechan-
isms: first, the proportion of sensitive and resistant cells
in the tumor could have been modified by the treatment
as chemotherapy may have killed erlotinib/gefitinib resis-
tant cells, and erlotinib/gefitinib sensitive cells have
become dominant. Secondly, chemotherapy may induce
novel genetic mutations in EGFR or other unknown asso-
ciated genes that regulated resistance to TKI.
Recently, some Asian cases have been described in
whom chemotherapy can restore gefitinib efficacy after
gefitinib resistance [16-18], indicating that drug resis-
tance may be reversible [19,20]. Gefitinib has been
reported to modulate the chemotherapy resistance of
NSCLC [21]. Several cancer cell line studies already
highlighted the importance of drug interaction between
TKI and taxane [22-24]. Thus, EGFR-TKIs and che-
motherapy may result in a sequence-dependent tumor
regression.
Based on the data herein, it is suggested that acquired
TKI resistance be managed aggressively whenever possi-
ble. Subsequent chemotherapy and target treatment are
one of the reasonable choices. Since TKI resistance
becomes increasingly important in the treatment of
NSCLC, our results provide promising insight for future
clinical practice and future investigations. Erlotinib/gefi-
tinib could be re-considered for those NSCLC patients
who had already benefited from prior erlotinib/gefitinib
treatment. Further studies are warranted to substantiate
the association of erlotinib /gefitinib treatment with the
efficacy of NSCLC patients with acquired TKI failure.
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